Journal of registry management · 2021
Predictors of Survival among Male and Female Patients with Malignant Pleural Mesothelioma: A Random Survival Forest Analysis of Data from the 2000-2017 Surveillance, Epidemiology, and End Results Program.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Bian, Niu Li, Boscoe Francis, Lee Furrina F
Аннотация
BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with a dismal prognosis. We aimed to identify predictors of survival among male and female MPM patients in the United States.
METHODS: We identified MPM cases reported by 18 cancer registries in the Surveillance, Epidemiology, and End Results Program (2000-2017). We applied a random survival forest (RSF) algorithm to identify and rank the importance of 10 variables at patient, cancer, and area level in predicting all-cause survival overall and by female and male subgroups.
RESULTS: Approximately 91.4% (n = 11,160) of the MPM patients had died, with better survival among females than males (11.7% vs 7.8%). The median follow-up time was 7 months (interquartile range, 2-17 months). A majority of the patients were male (78.6%), non-Hispanic White (81.8%), and residing in metropolitan counties with a population greater than 1 million (63.7%). The top 3 factors for predicting overall MPM survival were age, histological type, and cancer-directed surgery status. Except for age, the relative ranking of covariates varied by the 3 sample groups. Stage ranked fifth in predicting female survival, while it was replaced by metastasis status for male and overall patients. Race/ethnicity was not a good predictor for survival among MPM patients overall or the male subgroup, but ranked sixth for predicting survival among females. Median household income was not a good predictor for survival among females.
CONCLUSION: We demonstrated that RSF successfully identified predictors of MPM survival. RSF is a viable complement to the commonly used Cox proportional hazard model and a viable alternative, particularly when the proportional hazard assumption is unmet. RSF also identified differences between the sexes, which may help explain the sex differences in MPM survival rates.
METHODS: We identified MPM cases reported by 18 cancer registries in the Surveillance, Epidemiology, and End Results Program (2000-2017). We applied a random survival forest (RSF) algorithm to identify and rank the importance of 10 variables at patient, cancer, and area level in predicting all-cause survival overall and by female and male subgroups.
RESULTS: Approximately 91.4% (n = 11,160) of the MPM patients had died, with better survival among females than males (11.7% vs 7.8%). The median follow-up time was 7 months (interquartile range, 2-17 months). A majority of the patients were male (78.6%), non-Hispanic White (81.8%), and residing in metropolitan counties with a population greater than 1 million (63.7%). The top 3 factors for predicting overall MPM survival were age, histological type, and cancer-directed surgery status. Except for age, the relative ranking of covariates varied by the 3 sample groups. Stage ranked fifth in predicting female survival, while it was replaced by metastasis status for male and overall patients. Race/ethnicity was not a good predictor for survival among MPM patients overall or the male subgroup, but ranked sixth for predicting survival among females. Median household income was not a good predictor for survival among females.
CONCLUSION: We demonstrated that RSF successfully identified predictors of MPM survival. RSF is a viable complement to the commonly used Cox proportional hazard model and a viable alternative, particularly when the proportional hazard assumption is unmet. RSF also identified differences between the sexes, which may help explain the sex differences in MPM survival rates.